Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Fortune

Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

The Conversation

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Failure to Warn: The Type of Product Liability Ozempic is Being Sued for

Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. Recently, it has been in the spotlight due to lawsuits being filed against its manufacturer, Novo Nordisk. These lawsuits claim that Ozempic has been linked to a serious gastrointestinal condition called gastroparesis.

inkl

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Fortune

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Roll Call

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Roll Call

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Barchart

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

StockNews.com

Weight-loss drug Saxenda effective for kids as young as 6, study shows

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

The Independent UK

Ozempic maker sued over claims the weight-loss medication led to woman’s colon removal

Doctors had to remove parts of her intestines due to what she claims were side effects from taking weight-loss medication

The Independent UK

Scientists Confirmed An Important Connection Between Semaglutide and Mental Health

Researchers found that semaglutide, compared with a placebo, didn't significantly increase depressive thoughts.

Inverse

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Denmark gets Novo Nordisk to lower Ozempic prices

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

The Guardian - UK

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

Evening Standard

Weight loss drug Ozempic sales grow nearly 50% in the US, says maker Novo Nordisk

A surge in demand for weight loss drug Ozempic has helped Novo Nordisk post a 25% jump in revenues in the first half of the year, the Danish company said today.

Kiplinger

Should You Be Investing in Nordic Companies?

Should you be Investing in Nordic companies? This corner of Europe presents unique opportunities for investors.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Weight-loss drug could help slow Alzheimer’s cognitive decline, trial finds

Liraglutide appeared to reduce brain shrinkage in people with early-stage Alzheimer’s, a small UK study reports

Al Jazeera

Surging demand, soaring price tags lead to fake Ozempic doses

A rise in counterfeit versions of sought-after weight loss drug has led to a series of hospitalisations.

Fortune

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

The Independent UK

Weight-loss jab to be used to prevent other health problems

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Independent UK

Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

Zenger

Big Pharma’s Monopoly On Ozempic Threatens Access To Diabetes Drug In Communities Of Color

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

1 … 16 17 18 19

People

Lars Fruergaard Jørgensen

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

299 stories

Merck

294 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.